Ahmed T, Russi E, Kim C S, Danta I
Chest. 1985 Aug;88(2):176-80. doi: 10.1378/chest.88.2.176.
We investigated the comparative effects of oral and inhaled verapamil on specific airway conductance (SGaw) and allergic bronchial reactivity. Ten asymptomatic subjects with ragweed hypersensitivity and a history of bronchial asthma were studied on four different days, without and with pre-treatments by oral (160 mg) or inhaled (20 mg) verapamil. Bronchial reactivity was measured as the cumulative provocative dose of ragweed antigen which caused a 35 percent decrease in SGaw, ie PD35. The amount of inhaled verapamil actually deposited in the tracheobronchial tree was estimated to be 0.56 mg. Mean SGaw was not affected by either mode of administration; mean SGaw (SE) was 0.13(.02) and 0.12(.02) L/sec-1 before and .14(.02) and 0.12(.02) L/sec-1 after oral and inhaled verapamil, respectively. Mean (SE) PD35 was reproducible on two control days, ie 0.9(.4) and 0.8(.4) breath units, respectively. Inhaled verapamil increased mean PD35 to 18.8 (10.8) breath units (p less than 0.02), while oral verapamil had no significant effect on mean PD35. This study demonstrates that route of administration of calcium antagonist verapamil is an important factor in protection against antigen-induced bronchoconstriction. Inhalation of verapamil appears to be more effective than oral administration.
我们研究了口服和吸入维拉帕米对特定气道传导率（SGaw）和过敏性支气管反应性的比较效果。对10名患有豚草过敏且有支气管哮喘病史的无症状受试者在四个不同日期进行了研究，分别在未进行预处理以及口服（160毫克）或吸入（20毫克）维拉帕米预处理的情况下。支气管反应性通过导致SGaw降低35%的豚草抗原累积激发剂量来衡量，即PD35。估计实际沉积在气管支气管树中的吸入性维拉帕米量为0.56毫克。平均SGaw不受任何一种给药方式的影响；口服和吸入维拉帕米前平均SGaw（标准误）分别为0.13（0.02）和0.12（0.02）升/秒，给药后分别为0.14（0.02）和0.12（0.02）升/秒。在两个对照日，平均（标准误）PD35是可重复的，分别为0.9（0.4）和0.8（0.4）呼吸单位。吸入维拉帕米使平均PD35增加到18.8（10.8）呼吸单位（p小于0.02），而口服维拉帕米对平均PD35无显著影响。本研究表明，钙拮抗剂维拉帕米的给药途径是预防抗原诱导的支气管收缩的一个重要因素。吸入维拉帕米似乎比口服给药更有效。
